AstraZeneca Pharma receives permission from DCGI for Dapagliflozin Tablets

25 Jul 2023 Evaluate

AstraZeneca Pharma India has received Permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation - Additional Indication) from the Drugs Controller General of India (DCGI) for Dapagliflozin Tablets 10 mg. Through this approval, Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults. The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg in India for the specified indication, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.


Astrazeneca Pharma I Share Price

5447.15 2.60 (0.05%)
15-May-2024 11:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.65
Dr. Reddys Lab 5933.00
Cipla 1411.55
Zydus Lifesciences 993.80
Lupin 1631.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.